| 期刊簡介 | |||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
期刊名稱 | Lancet HIV LetPub Score 9.0
50 ratings
Rate
Reputation 9.9 Influence 8.6 Speed 7.0 | ||||||||||||||||||||||||||||
| 期刊簡稱 | LANCET HIV | ||||||||||||||||||||||||||||
| ISSN | 2352-3018 | ||||||||||||||||||||||||||||
| h-index | 34 | ||||||||||||||||||||||||||||
| CiteScore |
| ||||||||||||||||||||||||||||
| 自引率 (2023-2024) | 4.70%自引率趨勢 | ||||||||||||||||||||||||||||
| 掲載範囲 |
| ||||||||||||||||||||||||||||
| 官方網站 | http://www.journals.elsevier.com/the-lancet-hiv/ | ||||||||||||||||||||||||||||
| 在線稿件提交 | https://www.editorialmanager.com/THELANCETHIV | ||||||||||||||||||||||||||||
| 開放訪問 | No | ||||||||||||||||||||||||||||
| 出版商 | Elsevier Ltd | ||||||||||||||||||||||||||||
| 主題領域 | IMMUNOLOGYINFECTIOUS DISEASES& | ||||||||||||||||||||||||||||
| 出版國/地區 | ENGLAND | ||||||||||||||||||||||||||||
| 發行頻率 | |||||||||||||||||||||||||||||
| 創刊年 | 0 | ||||||||||||||||||||||||||||
| 每年文章數 | 64每年文章數趨勢 | ||||||||||||||||||||||||||||
| 黃金OA百分比 | 37.00% | ||||||||||||||||||||||||||||
| Web of Science 四分位 （ 2023-2024） | WOS Quartile: Q1
| ||||||||||||||||||||||||||||
| 索引 (SCI or SCIE) | Science Citation Index Expanded | ||||||||||||||||||||||||||||
| 鏈接到PubMed Central (PMC) | https://www.ncbi.nlm.nih.gov/nlmcatalog?term=2352-3018%5BISSN%5D | ||||||||||||||||||||||||||||
| 平均審稿時間 * | 來自出版商的數據: 來自作者的數據: | ||||||||||||||||||||||||||||
| 競爭力 * | 來自作者的數據: | ||||||||||||||||||||||||||||
| 參考鏈接 |
| ||||||||||||||||||||||||||||
| *所有的審稿過程指標，如接受率和審稿速度，僅限於用戶提交的稿件。因此，這些指標可能無法準確反映期刊的競爭力或速度。 | |||||||||||||||||||||||||||||
| |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
| [Lancet HIV] 的評論 | 撰寫評論 |
| 作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-30 22:22:40 評論於 The discussion section is the core part of a SCI paper, as it can demonstrate the breadth and depth of the author's research. Therefore, there is no specific word limit for this section. The length of the discussion section varies from article to article and from author to author, ranging from a few thousand words to tens of thousands of words  (0) 讚！ | 维尔娜菲茨杰拉德  |
| 作者: 维尔娜菲茨杰拉德 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-30 12:58:15 評論於 The discussion section is the core part of a SCI paper, as it reflects the breadth and depth of the author's research. Therefore, there is no specific word limit for this section. Depending on the article and the author, the length of the discussion section can vary greatly, ranging from a few thousand words to tens of thousands of words (0) 讚！ | 维尔娜菲茨杰拉德 |
| 作者: 北国博达 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-28 22:06:53 評論於 How many words are generally recommended for a discussion? (0) 讚！ | 北国博达 |
| 作者: 修然小公主 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2021-12-27 18:29:17 評論於 Is the lengthy discussion showing the author's deep thoughts on the topic? Did the reviewers have a positive impression of the manuscript? (0) 讚！ | 修然小公主 |
| 作者: 凌霄高洁 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2017-07-16 16:29:30 評論於 8-10 points is already very good, as long as it is maintained at this level in the long term, it is an international first-class journal (0) 讚！ | 凌霄高洁 |
| 作者: 北国梦菡 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2016-06-14 23:19:19 評論於 Review Speed: 2.0 | Submission Acceptance Rate: 25.0 Experience Sharing: Over 8 points, instantly fabulous! (0) 讚！ | 北国梦菡 |
| 作者: 神古苑博 領域: 医学 審稿時間: 0.0 month(s) 結果: 待定＆不明 撰寫評論 |
2016-02-16 11:55:29 評論於 Review speed: 1.0 | Submission acceptance rate: 25.0 Experience sharing: A new journal under Lancet, entering SCI, should be good (0) 讚！ | 神古苑博 |
| 首頁 上一頁 1 下一頁 末頁 (頁 | |
Contact us
